secwatch.observer — SEC 8-K summary
======================================

Issuer:     Summit Therapeutics Inc. (SMMT)
CIK:        0001599298
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001599298-26-000004
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Summit submits BLA for ivonescimab in EGFRm NSCLC; $710M cash; GSK collaboration
--------------------------------------------------------------------------------

- BLA submitted to FDA for ivonescimab + chemo in 2L+ EGFR-mutated NSCLC based on Phase III HARMONi; FDA decision expected Q4 2026.
- Preliminary cash, cash equivalents, and short-term investments of ~$710M as of Dec 31, 2025.
- Clinical collaboration with GSK to evaluate ivonescimab + risvutatug rezetecan (B7-H3 ADC) across solid tumors; dosing expected mid-2026.
- Over 14,000 patients in the US annually eligible for 2L+ treatment of EGFRm NSCLC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1599298/000159929826000004/0001599298-26-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1599298/000159929826000004/smmt-20260112.htm
  HTML page:      https://secwatch.observer/filing/0001599298-26-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer